Capital Asset Advisory Services LLC Acquires New Stake in Edwards Lifesciences Corporation $EW

Key Points

• Capital Asset Advisory Services LLC has acquired a new stake in Edwards Lifesciences Corporation, purchasing 5,853 shares valued at approximately $452,000.
• Several large investors, including Brighton Jones LLC and Gotham Asset Management LLC, have also increased their stakes, with institutional investors collectively owning 79.46% of the company's stock.
• Analysts have raised price targets for Edwards Lifesciences, with Stifel Nicolaus setting a new target of $95.00 and a consensus rating of "Moderate Buy" among analysts.

Capital Asset Advisory Services LLC acquired a new stake in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 5,853 shares of the medical research company's stock, valued at approximately $452,000.

Other large investors also recently bought and sold shares of the company. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences in the 4th quarter worth $266,000. Bank Pictet & Cie Europe AG lifted its holdings in shares of Edwards Lifesciences by 16.7% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 10,231 shares of the medical research company's stock worth $757,000 after buying an additional 1,463 shares during the period. Gotham Asset Management LLC lifted its holdings in shares of Edwards Lifesciences by 105.8% in the 4th quarter. Gotham Asset Management LLC now owns 16,423 shares of the medical research company's stock worth $1,216,000 after buying an additional 8,444 shares during the period. ProShare Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 10.3% in the 4th quarter. ProShare Advisors LLC now owns 90,668 shares of the medical research company's stock worth $6,712,000 after buying an additional 8,491 shares during the period. Finally, Rafferty Asset Management LLC lifted its holdings in shares of Edwards Lifesciences by 9.5% in the 4th quarter. Rafferty Asset Management LLC now owns 66,887 shares of the medical research company's stock worth $4,952,000 after buying an additional 5,788 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analysts Set New Price Targets

EW has been the subject of several research reports. Stifel Nicolaus upped their target price on Edwards Lifesciences from $90.00 to $95.00 and gave the stock a "buy" rating in a report on Friday, July 25th. Canaccord Genuity Group upped their price objective on Edwards Lifesciences from $75.00 to $81.00 and gave the stock a "hold" rating in a research note on Friday, July 25th. William Blair raised Edwards Lifesciences to a "strong-buy" rating in a research report on Friday, July 25th. Citigroup reaffirmed a "buy" rating and set a $95.00 target price (up from $84.00) on shares of Edwards Lifesciences in a research report on Thursday, May 22nd. Finally, Truist Financial upped their target price on Edwards Lifesciences from $81.00 to $82.00 and gave the company a "hold" rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Edwards Lifesciences presently has a consensus rating of "Moderate Buy" and a consensus price target of $86.26.

Edwards Lifesciences Stock Down 0.7%

Edwards Lifesciences stock opened at $77.50 on Monday. The firm has a market cap of $45.50 billion, a price-to-earnings ratio of 11.15, a price-to-earnings-growth ratio of 3.74 and a beta of 1.07. The business's 50-day moving average price is $78.92 and its 200 day moving average price is $75.45. The company has a quick ratio of 3.87, a current ratio of 4.68 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The company had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.Edwards Lifesciences's revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the firm's stock in a transaction on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company's stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company's stock, valued at $16,150,614. The trade was a 4.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.34% of the stock is owned by company insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.